Metabolic & Cardiometabolic

GLP-1 receptor agonists causes GI side effects via delayed gastric emptying (nausea, vomiting; rare gastroparesis)

In plain terms: Do GLP-1 drugs commonly cause stomach and GI side effects?

Strong support Metabolic & Cardiometabolic

RefutedContestedStrong support

consensus score 0.96

Very commonly nausea, vomiting, diarrhea and constipation — usually mild/transient and tied to delayed gastric emptying — with a small but real increase in rarer events like gastroparesis and bowel obstruction.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

30 support 0 contradict 0 tested null 1 mixed · 31 sources, 30 independent groups

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2025 · see review Agrees with our grade

Cochrane frames absolute clinical relevance as limited at medium-term but relevant long-term.

“Same review (CD015092.pub2): 'While semaglutide increases the risk of adverse events leading to withdrawal, it appears to be of limited clinical relevance in absolute terms at medium-term, and clinically relevant at long-term follow-up.'”

Why we agree: we reached the same direction independently, from our own appraisal of 31 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (31)

Source	Grade	Stance	Quality	Finding
Blundell 2018 · Diabetes Obes Metab	RCT	supports	high	Mechanism: semaglutide delayed first-hour gastric emptying in obesity (crossover), linking emptying delay to early satiety/nausea.
Zaitoon H et al 2025 · study_type: observational	observational	supports	low	Review of pediatric GLP-1RA use: a trial in children 6-<12 years showed liraglutide reduced BMI vs placebo 'with GI events consistent with prior safety profiles.'
Kim MK et al 2026 · study_type: observational	observational	supports	moderate	Narrative review of GLP-1RA safety profile; discusses adverse events including retained gastric content and pulmonary aspiration as concerns despite metabolic benefits.
Xie 2025 · Diabetes Metab Syndr Obes	meta-analysis	supports	moderate	GLP-1/GIP co-agonists vs GLP-1RA: greater weight loss comes with higher GI adverse-event burden.
Sekhon S et al 2026 · study_type: observational	observational	supports	low	Case report: 32F developed hematochezia/abdominal pain after 6 weeks of tirzepatide, biopsy-confirmed ischemic colitis; temporal relationship supports drug-induced GI complication.
Witaszek T et al 2025 · study_type: observational	observational	supports	moderate	Review of GI symptoms in obesity therapy: GI AEs reported in 65-84% of patients on liraglutide, semaglutide, or tirzepatide, mainly nausea and diarrhea, attributed to altered gastric motility.
Newsome 2021 · N Engl J Med	RCT	supports	high	MASH trial: nausea 42% vs 11%, vomiting 15% vs 2%, constipation 22% vs 12% with semaglutide — reproduces GI signal across indications.
Xie X et al 2025 · study_type: meta-analysis	meta-analysis	supports	high	Bayesian network meta-analysis (48 RCTs, n=27,729): overall GI AE incidence 11.66%, nausea most frequent (21.49%); tirzepatide highest risk of nausea/diarrhea, dulaglutide/exenatide most tolerable.
Jones M et al] # corrected 2026-08-17 from PubMed; was [2025 venue: Cureus · Cureus	observational	supports	low	Case report/review: rare bowel obstruction with GLP-1RA; biologically plausible via motility slowing, but causality uncertain in case data.
Jalleh RJ et al 2026 · study_type: observational	observational	supports	moderate	Narrative review: GLP-1RA treatment slows gastric emptying, increasing propensity for retained gastric contents and aspiration risk during endoscopy/anesthesia; calls for standardized GI symptom assessment.
Dahl 2021 · Diabetes Obes Metab	RCT	supports	moderate	Oral semaglutide delayed gastric emptying and improved postprandial glucose in T2D crossover — confirms emptying mechanism.
Qian Z et al 2026 · study_type: observational	observational	supports	moderate	FAERS/CVARD pharmacovigilance disproportionality analysis (>58M reports): semaglutide showed strongest signal for impaired gastric emptying among 50 screened drugs (ROR 80.27, 95% CI 76.39-84.34; validated in CVARD ROR 54.17).
Wilding 2021 · N Engl J Med	RCT	supports	high	STEP-1: nausea 44%, diarrhea 32%, vomiting 25%, constipation 24% with semaglutide vs much lower placebo; mostly mild-moderate, transient.
Kristensen 2019 · Lancet Diabetes Endocrinol	meta-analysis	supports	high	CVOT MA notes GI AEs are the principal tolerability limitation of the class, exceeding placebo across trials.
Hageen AW et al 2026 · study_type: meta-analysis	meta-analysis	supports	high	Network meta-analysis of RCTs: orforglipron 45mg vs placebo increased nausea (OR 11.48, 95% CI 6.52-20.21), vomiting (OR 11.48), diarrhoea (OR 3.99, 95% CI 2.07-7.70), discontinuation due to GI AEs (OR 10.22), with clear dose-response acros
McKenzie C et al 2025 · study_type: observational	observational	supports	low	Narrative review for dental anesthesia providers: GLP-1/GIP receptor agonists decrease gastric emptying, increasing satiety but also risk of retained gastric contents, emesis, and aspiration perioperatively.
Wharton 2022 · Diabetes Obes Metab	RCT	supports	high	STEP pooled GI tolerability: GI AEs concentrated during dose escalation, typically transient; modest extra weight loss in those affected.
Manoj RJ et al 2026 · study_type: observational	observational	supports	low	Review of incretin polyagonists vs bariatric surgery; notes some agents display 'a favorable side effect profile' enhancing tolerability, implying GI effects remain relevant but improving.
Kanbay M et al 2026 · study_type: meta-analysis	meta-analysis	supports	moderate	Systematic review/meta-analysis (17 studies, n=54,680 kidney transplant recipients): GLP-1RA adverse events were mainly mild GI intolerance (10-20%), with rare discontinuations.
Sodhi 2023 · JAMA	observational	supports	moderate	Pharmacoepi cohort (weight-loss use): GLP-1RA vs bupropion-naltrexone raised gastroparesis (HR 3.67, 1.15-11.90), bowel obstruction and pancreatitis.
Aronne 2025 · N Engl J Med	RCT	supports	high	SURMOUNT-5: GI AEs most common in both arms; mostly mild-moderate, consistent with mechanism, more frequent on tirzepatide.
Merhavy ZI et al 2026 · study_type: meta-analysis	observational	supports	moderate	Systematic review (32 studies) of GLP-1RA and perioperative aspiration risk: most studies found association with increased residual gastric contents, but evidence linking GLP-1RA to statistically significant rise in regurgitation/aspiration
Takrori E et al 2025 · study_type: meta-analysis	observational	supports	moderate	Systematic review (12 studies, incl. cohort of 18,386) of GI AEs of anti-obesity medications in non-diabetic adults: nausea, vomiting, diarrhea, constipation most frequently reported, predominantly with GLP-1RAs (semaglutide, tirzepatide) e
Wen J et al 2025 · study_type: observational	observational	supports	moderate	Retrospective study (n=144 EGD patients): 11/12 patients on semaglutide/tirzepatide >6 months had residual gastric content vs 0/132 not meeting duration criteria (p<0.001).
Lorenz N et al 2025 · study_type: observational	observational	supports	low	Case report: 52F with no surgical history developed functional small bowel obstruction after tirzepatide (Zepbound) dose escalation, no other identifiable cause.
de Mesquita 2023 · Int J Obes	meta-analysis	supports	moderate	Tirzepatide RCT MA: dose-dependent nausea/diarrhea/vomiting drive most discontinuations; class-consistent GI profile.
Kansakar U et al 2026 · study_type: observational	observational	supports	low	Narrative review of orforglipron notes phase 1-3 trials showed 'acceptable safety profile' alongside efficacy for glycemic/weight endpoints; no specific GI AE rates extracted.
Radparvar I et al 2025 · study_type: observational	observational	supports	low	Narrative analysis of incretin-based therapies noting adverse effects are most commonly gastrointestinal disturbances, less frequently gallbladder disease, pancreatitis, or ophthalmologic concerns.
Rallabandi S et al 2026 · study_type: observational	n-of-1	supports	low	Case report: 59F on semaglutide (dose increase 0.25→0.5mg) developed nausea, vomiting, abdominal pain progressing to small bowel obstruction from severe ileus and AKI requiring dialysis.
Crisafulli S et al] # corrected 2026-08-17 from PubMed; was [2026 venue: Ann Intern Med · Ann Intern Med	observational	mixed	high	Comparative GI safety T2D cohort: GI event HRs near 1.0 between semaglutide/dulaglutide/tirzepatide — relative parity among agents (vs each other).
Nahar S et al 2025 · study_type: observational	n-of-1	supports	low	Case report: 61F on long-term tirzepatide developed progressive constipation then severe small bowel obstruction requiring surgery; authors attribute contributory role to tirzepatide-induced motility changes.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.